

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Roflumilast 0.3% Foam (Zoryve)

Notes:

- Quantity Limits: Yes
- ^Adequate trial is defined as 8 weeks treatment duration
- *Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria, criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously, and criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **roflumilast 0.3% foam (Zoryve)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescriber is a dermatologist
- Patient has a diagnosis of seborrheic dermatitis that covers 10 percent of the body surface area
- Patient is 9 years of age or older
- Patient has failed an adequate trial[^], or patient has an allergy or intolerance* to all of the following:
 - At least 1 topical steroid
 - At least 1 topical calcineurin inhibitor (e.g. tacrolimus 0.1% ointment)
 - At least 1 topical antifungal
 - Selenium sulfide

Continued use criteria for patients previously approved per the above criteria who are currently stable on the medication: Non-formulary **roflumilast 0.3% foam (Zoryve)** will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescriber is a dermatologist
- Patient has responded to roflumilast 0.3% foam as determined by prescriber